Metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline

American Journal of Neurodegenerative Diseases

Volumn 5, Issue 5, 2016, Pages 171-177

  Wang, Maggie ^a   Norman, Jennifer E ^a   Srinivasan, Vivek J ^b   Rutledge, John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California Davis   (United States)

Author keywords

Alzheimer s disease; Cognitive impairment; Dementia; Inflammation; Neurodegenerative disorders; Vascular biology; Western diet; White matter disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

ARTERIAL STIFFNESS; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIA; METABOLIC ACTIVATION; METABOLIC SYNDROME X; MICROVASCULATURE; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREVALENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOCYTE ACTIVATION; WHITE MATTER LESION;

EID: 85009487450     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Xu J, Murphy SL, Kochanek KD and Bastian BA. Deaths: Final Data for 2013. Natl Vital Stat Rep 2016; 64: 1-119.
2. Hebert LE, Weuve J, Scherr PA and Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80: 1778-1783.
3. Jacka FN, Pasco JA, Mykletun A, Williams LJ, Hodge AM, O’Reilly SL, Nicholson GC, Kotowicz MA and Berk M. Association of Western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010; 167: 305-311.
4. Jacka FN, Cherbuin N, Anstey KJ and Butterworth P. Dietary Patterns and Depre-ssive Symptoms over Time: Examining the Relationships with Socioeconomic Position, Health Behaviours and Cardiovascular Risk. PLoS One 2014; 9: e87657.
5. Jacka FN, Cherbuin N, Anstey KJ, Sachdev P and Butterworth P. Western diet is associated with a smaller hippocampus: a longitudinal investigation. BMC Med 2015; 13: 215.
6. Dearborn JL, Knopman D, Sharrett AR, Schneider AL, Jack CR Jr, Coker LH, Alonso A, Selvin E, Mosley TH, Wagenknecht LE, Windham BG and Gottesman RF. The metabolic syndrome and cognitive decline in the Atherosclerosis Risk in Communities study (ARIC). Dement Geriatr Cogn Disord 2014; 38: 337-346.
7. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H and Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993; 43: 1683-1689.
8. Debette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341: c3666.
9. Fernando MS and Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004; 226: 13-17.
10. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME and Brickman AM. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol 2013; 70: 455-461.
11. Kandiah N, Mak E, Ng A, Huang S, Au WL, Sitoh YY and Tan LC. Cerebral white matter hyperintensity in Parkinson’s disease: a major risk factor for mild cognitive impairment. Parkin-sonism Relat Disord 2013; 19: 680-683.
12. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neurop-sychology 2000; 14: 224-232.
13. Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, Brandt J, Blacker D and Stern Y. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol 2008; 65: 1202-1208.
14. Friedman JI, Tang CY, de Haas HJ, Changchien L, Goliasch G, Dabas P, Wang V, Fayad ZA, Fuster V and Narula J. Brain imaging changes associated with risk factors for cardiovascular and cerebrovascular disease in asymptomatic patients. JACC Cardiovasc Imaging 2014; 7: 1039-1053.
15. Espeland MA, Erickson K, Neiberg RH, Jakicic JM, Wadden TA, Wing RR, Desiderio L, Erus G, Hsieh MK, Davatzikos C, Maschak-Carey BJ, Laurienti PJ, Demos-McDermott K, Bryan RN; Action for Health in Diabetes Brain Magnetic Resonance Imaging (Look AHEAD Brain) Ancillary Study Research Group. Brain and White Matter Hyperintensity Volumes After 10 Years of Random Assignment to Lifestyle Intervention. Diabetes Care 2016; 39: 764-771.
16. Kullmann S, Schweizer F, Veit R, Fritsche A and Preissl H. Compromised white matter integrity in obesity. Obes Rev 2015; 16: 273-281.
17. Gardener H, Scarmeas N, Gu Y, Boden-Albala B, Elkind MS, Sacco RL, DeCarli C and Wright CB. Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study. Arch Neurol 2012; 69: 251-256.
18. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND). Diabetes Care 2009; 32: 221-226.
19. Stephen CW, Randy JS, Denis GB and Michael WS. Insulin and the Blood-Brain Barrier. Curr Pharm Des 2003; 9: 795-800.
20. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA and Masliah E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer’s disease and correction by insulin. J Neurosci Res 2008; 86: 3265-3274.
21. Ramos-Rodriguez JJ, Jimenez-Palomares M, Murillo-Carretero MI, Infante-Garcia C, Berro-coso E, Hernandez-Pacho F, Lechuga-Sancho AM, Cozar-Castellano I and Garcia-Alloza M. Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer’s disease. Psychoneuroendo-crinology 2015; 62: 69-79.
22. Ramos-Rodriguez JJ, Spires-Jones T, Pooler AM, Lechuga-Sancho AM, Bacskai BJ and Garcia-Alloza M. Progressive Neuronal Patho-logy and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer’s Disease. Mol Neurobiol 2016; [Epub ahead of print].
23. Convit A. Links between cognitive impairment in insulin resistance: An explanatory model. Neurobiol Aging 2005; 26 Suppl 1: 31-35.
24. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP and Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71: 1057-1064.
25. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B and Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011; 76: 1568-1574.
26. Karmi A, Iozzo P, Viljanen A, Hirvonen J, Fielding BA, Virtanen K, Oikonen V, Kemppainen J, Viljanen T, Guiducci L, Haaparanta-Solin M, Nagren K, Solin O and Nuutila P. Increased brain fatty acid uptake in metabolic syndrome. Diabetes 2010; 59: 2171-2177.
27. Freeman LR, Zhang L, Nair A, Dasuri K, Francis J, Fernandez-Kim SO, Bruce-Keller AJ and Keller JN. Obesity increases cerebrocortical reactive oxygen species and impairs brain function. Free Radic Biol Med 2013; 56: 226-233.
28. Alosco ML, Spitznagel MB, Strain G, Devlin M, Cohen R, Paul R, Crosby RD, Mitchell JE and Gunstad J. Improved memory function two years after bariatric surgery. Obesity (Silver Spring) 2014; 22: 32-38.
29. Pistell PJ, Morrison CD, Gupta S, Knight AG, Keller JN, Ingram DK and Bruce-Keller AJ. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol 2010; 219: 25-32.
30. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S and Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76-80.
31. Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, Blankenstein MA and Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 2009; 30: 1885-1889.
32. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM and Yan SD. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
33. Lue LF, Andrade C, Sabbagh M and Walker D. Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer’s Disease? Int J Alzheimers Dis 2012; 2012: 918680.
34. Gorska-Ciebiada M, Saryusz-Wolska M, Bor-kowska A, Ciebiada M and Loba J. C-Reactive Protein, Advanced Glycation End Products, and Their Receptor in Type 2 Diabetic, Elderly Patients with Mild Cognitive Impairment. Front Aging Neurosci 2015; 7: 209.
35. Woodling NS, Colas D, Wang Q, Minhas P, Panchal M, Liang X, Mhatre SD, Brown H, Ko N, Zagol-Ikapitte I, van der Hart M, Khroyan TV, Chuluun B, Priyam PG, Milne GL, Rassoulpour A, Boutaud O, Manning-Bog AB, Heller HC and Andreasson KI. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer’s disease model mice. Brain 2016; 139: 2063-81.
36. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH and Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A[beta]42 production. Nat Med 2005; 11: 545-550.
37. Benedetti F, Poletti S, Hoogenboezem TA, Mazza E, Ambree O, de Wit H, Wijkhuijs AJ, Locatelli C, Bollettini I, Colombo C, Arolt V and Drexhage HA. Inflammatory cytokines influence measures of white matter integrity in Bipolar Disorder. J Affect Disord 2016; 202: 1-9.
38. Kuriyama N, Mizuno T, Yasuike H, Matsuno H, Kawashita E, Tamura A, Ozaki E, Matsui D, Watanabe I, Koyama T, Miyatani F, Kondo M, Tokuda T, Ohshima Y, Muranishi M, Akazawa K, Takada A, Takeda K, Matsumoto S, Mizuno S, Yamada K, Nakagawa M and Watanabe Y. CD62-mediated activation of platelets in cerebral white matter lesions in patients with cognitive decline. Arch Gerontol Geriatr 2016; 62: 118-124.
39. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y and Shinkai S. Prospective Study of Arterial Stiffness and Subsequent Cognitive Decline Among Community-Dwelling Older Japanese. J Epidemiol 2015; 25: 592-599.
40. Gutierrez J, Marshall RS and Lazar RM. Indirect measures of arterial stiffness and cognitive performance in individuals without traditional vascular risk factors or disease. JAMA Neurol 2015; 72: 309-315.
41. Tsao CW, Himali JJ, Beiser AS, Larson MG, DeCarli C, Vasan RS, Mitchell GF and Seshadri S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology 2016; 86: 619-626.
42. Saji N, Shimizu H, Kawarai T, Tadano M, Kita Y and Yokono K. Increased brachial-ankle pulse wave velocity is independently associated with white matter hyperintensities. Neuroepidemio-logy 2011; 36: 252-257.
43. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ and Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008; 39: 2712-2719.
44. Smallwood A, Oulhaj A, Joachim C, Christie S, Sloan C, Smith AD and Esiri M. Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol 2012; 38: 337-343.
45. Brickman AM, Zahra A, Muraskin J, Steffener J, Holland CM, Habeck C, Borogovac A, Ramos MA, Brown TR, Asllani I and Stern Y. Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res 2009; 172: 117-120.
46. Efimova IY, Efimova NY, Triss SV and Lishmanov YB. Brain perfusion and cognitive function changes in hypertensive patients. Hypertens Res 2008; 31: 673-678.
47. Pallebage-Gamarallage M, Lam V, Takechi R, Galloway S, Clark K and Mamo J. Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids Health Dis 2012; 11: 117.
48. Freeman LR and Granholm AC. Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet. J Cereb Blood Flow Metab 2012; 32: 643-653.
49. Davidson TL, Monnot A, Neal AU, Martin AA, Horton JJ and Zheng W. The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood-brain barrier integrity differ for diet-induced obese and diet-resistant rats. Physiol Behav 2012; 107: 26-33.
50. Gauthier JM and Massicotte A. Statins and their effect on cognition: Let’s clear up the confusion. Can Pharm J 2015; 148: 150-155.